BioChem Pharma 1Q Net C$0.40/Shr Vs Net Cont Op C$0.28
Dow Jones Newswires
BioChem Pharma Inc. - Laval, Que.
1st Quar March 31:
All figures in Canadian dollars
2000 1999
Revenues C$72,517,000 C$62,722,000
Inc cnt op a 40,429,000 30,206,000
Inc dis op .... (1,097,000)
Net income a 40,429,000 29,109,000
Avg shares 101,130,753 108,914,873
Shr ern (basic)
Inc cnt op a .40 .28
Inc dis op .... (.01)
Net income a .40 .27
a. Includes a gain of C$3,776,000 or 4 Canadian cents a
share on the sale of long-term investments.
The company said its main revenue source is royalties on
two out-licensed products, 3TC/Epivir for HIV/AIDS and
Zeffix for chronic hepatitis B.
It said first-quarter royalty revenue increased 10% to
C$42.7 million. Research and development contracts added
C$15.4 million to revenues, compared with C$16.4 million a
year earlier, it said.
BioChem said research and development spending in the first
quarter was C$16.7 million, compared with C$20.3 million a
year earlier. |
